FDA Approved: CALCIPOTRIENE — Supplemental Application (Prasco Laboratories)

View source ↗

Summary

FDA records a supplemental application for calcipotriene submitted by Prasco Laboratories (NDA 020554). The submission status is AP (supplemental approval).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• Calcipotriene (calcipotriene)

Snippet

SUPPL AP for CALCIPOTRIENE (CALCIPOTRIENE)